How beautiful is South Korea and the United States under Lilly Sanofi Johnson's skirt?

Source: two transactions of health idea ihealth in 2015-11-11 exceeded US $5 billion in five days A world-class pharmaceutical company in Seoul has attracted global attention If there is a word to sum up, it is that the sky in November leaves roses in Korea and the United States First, it was contracted on November 4 to sign a license agreement with Sanofi from France for diabetes treatment Globally, Sanofi has developed a combination of long-term diabetes treatments developed by South Korea and the United States, with a transaction value of 3.9 billion euros ($4.2 billion) including an upfront payment of 400 million euros The deal not only set a new record for licensing agreements between South Korea and the United States, but also inadvertently raised the value of South Korea and the United States overnight Shares in South Korea and the US rose 30% for the second day in a row Five days later, on November 9, the deal with Johnson & Johnson was finalized Under the agreement, Johnson's Janssen will receive global rights, excluding China and South Korea, to develop and commercialize acid regulation based therapies, including hm12525a for diabetes and obesity South Korea and the United States will receive $105 million and qualify for clinical, management and sales milestones of up to $810 million, plus tiered double-digit royalties If it's too busy for South Korea and the United States, it's a big underestimate of her strength Sanofi's deal with Johnson & Johnson is the fourth and fifth between South Korea and the United States this year In March, she reached a $690 million contract with Lilly for the tyrosine kinase (Btk) inhibitor hm71224 Four months later, she was on the signing table again, signing a contract worth as much as $730 million with the German pharmaceutical company bringer Ingelheim to transfer her new non-small cell lung cancer (NSCLC) treatment drug hm61713 What's more amazing is that the beauty of South Korea and the United States may not be stopped Because her list of candidates is still attractive Among its research and development channels, rhGH (hm10560a), kx2-391, a SRC inhibitor and tubulin destabilizer for the treatment of solid tumors, and hm95573, a selective pan RAF inhibitor, are also included Potential targets include cancer caused by b-rafmut / n-rasmut / c-raf Success is not just a chance development strategy awesome In 2014, Korea and the United States invested the first 150 billion yuan in research and development, targeting cancer and targeting the world market However, many Korean pharmaceutical companies are actively increasing R & D, why are Korea and the United States so attractive? According to a report of hi investment securities company, a Korean investment company, due to its size and resource constraints, although many Korean pharmaceutical companies are actively increasing R & D, it is actually impossible for most companies to independently explore candidate compounds and complete clinical trials, and launch all products to the development stage In the face of challenges, how to develop new drugs in a short time, hi investment suggests two ways to shorten the development line What is reflected in South Korea and the United States is a case focusing on specific areas The Korean pharmaceutical company specializes in cancer, diabetes and digestion In these areas, the humble companies can also transfer licenses in the early detection stage or phase I clinical trial stage to increase their R & D success rate Hm71224 as an example, this Btk inhibitor has been developed by Johnson & Johnson company, imbruvica (ibrutinib), becoming the first Btk new drug in the molecular like treatment of chronic lymphocytic leukemia, and was approved by the US FDA in November 2013 two years ago In addition, various other Btk inhibitors are being developed, and all hm71224 from Korea and the United States are in clinical trials in advance In such an environment, South Korea and the United States decided to initially develop a drug for the treatment of rheumatoid arthritis, rather than cancer, because it costs less and is more difficult to conduct clinical trials In this way, hm71224 can be developed at a rapid speed, and it is relatively easy to succeed in phase I clinical trials, said hi investment securities analysis Another way is to develop botanical drugs that are exempt from phase I clinical research In general, the research and development of a new drug will take about 10 years or more, but due to the long-term use experience and established safety, the early clinical trials can be exempted in most cases, so that they can get the green light of supervision within two to three years, thus shortening the development cycle This strategy applies to South Korea as well as the United States East Asia ST company is the executor of the second strategy The large Korean pharmaceutical company has developed a number of new botanical drugs and recently completed a second phase of herbal derived diabetic neuropathy pain drugs in the United States, including da-9801 Now, East Asia is actively looking for the right man to marry da-9801 on a global scale.